Carlsmed, Inc. (NASDAQ: CARL) Stock Competitors & Peer Comparison

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ABT has a market cap of 184.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ABT trades at $105.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ABT's P/E ratio is 20.30. In terms of profitability, CARL's ROE is -0.62%, compared to ABT's ROE of +0.11%. Regarding short-term risk, CARL is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ABT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CARL's ROE is -0.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CARL is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for CARL.Check BSX-PA's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SYK has a market cap of 124.9B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SYK trades at $325.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SYK's P/E ratio is 24.32. In terms of profitability, CARL's ROE is -0.62%, compared to SYK's ROE of +0.16%. Regarding short-term risk, CARL is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for CARL.Check SYK's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, MDT has a market cap of 109.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while MDT trades at $85.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas MDT's P/E ratio is 15.44. In terms of profitability, CARL's ROE is -0.62%, compared to MDT's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check MDT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BSX has a market cap of 69.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BSX trades at $46.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BSX's P/E ratio is 15.07. In terms of profitability, CARL's ROE is -0.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, CARL is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BSX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while EW trades at $86.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas EW's P/E ratio is 31.87. In terms of profitability, CARL's ROE is -0.62%, compared to EW's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for CARL.Check EW's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, DXCM has a market cap of 32.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while DXCM trades at $83.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas DXCM's P/E ratio is 35.82. In terms of profitability, CARL's ROE is -0.62%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, CARL is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for CARL.Check DXCM's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, RMD has a market cap of 30.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while RMD trades at $210.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas RMD's P/E ratio is 19.59. In terms of profitability, CARL's ROE is -0.62%, compared to RMD's ROE of +0.24%. Regarding short-term risk, CARL is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check RMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PHG trades at $26.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PHG's P/E ratio is 15.03. In terms of profitability, CARL's ROE is -0.62%, compared to PHG's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for CARL.Check PHG's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ZBH trades at $93.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ZBH's P/E ratio is 11.08. In terms of profitability, CARL's ROE is -0.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CARL is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ZBH's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CARL's ROE is -0.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ABMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SNN trades at $31.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SNN's P/E ratio is 17.02. In terms of profitability, CARL's ROE is -0.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CARL is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SNN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PEN trades at $321.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PEN's P/E ratio is 83.87. In terms of profitability, CARL's ROE is -0.62%, compared to PEN's ROE of +0.11%. Regarding short-term risk, CARL is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check PEN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CARL's ROE is -0.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CARL is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SWAV's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ALGN trades at $169.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ALGN's P/E ratio is 15.81. In terms of profitability, CARL's ROE is -0.62%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ALGN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PODD has a market cap of 11.5B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PODD trades at $165.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PODD's P/E ratio is 30.73. In terms of profitability, CARL's ROE is -0.62%, compared to PODD's ROE of +0.21%. Regarding short-term risk, CARL is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check PODD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while GMED trades at $78.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas GMED's P/E ratio is 17.75. In terms of profitability, CARL's ROE is -0.62%, compared to GMED's ROE of +0.13%. Regarding short-term risk, CARL is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for CARL.Check GMED's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, GKOS has a market cap of 9.8B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while GKOS trades at $166.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas GKOS's P/E ratio is -194.15. In terms of profitability, CARL's ROE is -0.62%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, CARL is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for CARL.Check GKOS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BRKR trades at $62.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BRKR's P/E ratio is 34.53. In terms of profitability, CARL's ROE is -0.62%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, CARL is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BRKR's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas MASI's P/E ratio is 44.43. In terms of profitability, CARL's ROE is -0.62%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CARL is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for CARL.Check MASI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BIO-B has a market cap of 9.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BIO-B trades at $320.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BIO-B's P/E ratio is 95.08. In terms of profitability, CARL's ROE is -0.62%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, CARL is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for CARL.Check BIO-B's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BIO has a market cap of 8.8B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BIO trades at $325.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BIO's P/E ratio is 35.12. In terms of profitability, CARL's ROE is -0.62%, compared to BIO's ROE of +0.02%. Regarding short-term risk, CARL is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for CARL.Check BIO's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas NARI's P/E ratio is -59.24. In terms of profitability, CARL's ROE is -0.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CARL is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for CARL.Check NARI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while LIVN trades at $80.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas LIVN's P/E ratio is 20.04. In terms of profitability, CARL's ROE is -0.62%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, CARL is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check LIVN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ITGR has a market cap of 4.1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ITGR trades at $121.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ITGR's P/E ratio is 19.24. In terms of profitability, CARL's ROE is -0.62%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, CARL is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for CARL.Check ITGR's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, HAE has a market cap of 3.9B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while HAE trades at $85.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas HAE's P/E ratio is 17.22. In terms of profitability, CARL's ROE is -0.62%, compared to HAE's ROE of +0.11%. Regarding short-term risk, CARL is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for CARL.Check HAE's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while IRTC trades at $117.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas IRTC's P/E ratio is -209.23. In terms of profitability, CARL's ROE is -0.62%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, CARL is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for CARL.Check IRTC's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CARL's ROE is -0.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CARL is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for CARL.Check AXNX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ESTA trades at $92.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ESTA's P/E ratio is -64.26. In terms of profitability, CARL's ROE is -0.62%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, CARL is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ESTA's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while TMDX trades at $76.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas TMDX's P/E ratio is 31.23. In terms of profitability, CARL's ROE is -0.62%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, CARL is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for CARL.Check TMDX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AXGN trades at $42.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AXGN's P/E ratio is 111.08. In terms of profitability, CARL's ROE is -0.62%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, CARL is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for CARL.Check AXGN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CARL's ROE is -0.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CARL is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for CARL.Check NUVA's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while UFPT trades at $254.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas UFPT's P/E ratio is 26.54. In terms of profitability, CARL's ROE is -0.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CARL is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check UFPT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BFLY trades at $7.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BFLY's P/E ratio is -29.60. In terms of profitability, CARL's ROE is -0.62%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, CARL is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BFLY's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while NVCR trades at $14.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas NVCR's P/E ratio is -9.70. In terms of profitability, CARL's ROE is -0.62%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, CARL is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for CARL.Check NVCR's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ENOV has a market cap of 1.7B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ENOV trades at $29.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ENOV's P/E ratio is 8.63. In terms of profitability, CARL's ROE is -0.62%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, CARL is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ENOV's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ATEC trades at $9.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ATEC's P/E ratio is -86.55. In terms of profitability, CARL's ROE is -0.62%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, CARL is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ATEC's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AHCO trades at $10.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AHCO's P/E ratio is 24.27. In terms of profitability, CARL's ROE is -0.62%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, CARL is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for CARL.Check AHCO's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, INSP has a market cap of 1.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while INSP trades at $50.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas INSP's P/E ratio is 19.43. In terms of profitability, CARL's ROE is -0.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, CARL is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for CARL.Check INSP's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CNMD trades at $46.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CNMD's P/E ratio is 10.21. In terms of profitability, CARL's ROE is -0.62%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, CARL is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check CNMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while TNDM trades at $19.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas TNDM's P/E ratio is -17.73. In terms of profitability, CARL's ROE is -0.62%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, CARL is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for CARL.Check TNDM's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CARL's ROE is -0.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CARL is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for CARL.Check HSKA's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AORT trades at $26.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AORT's P/E ratio is 41.26. In terms of profitability, CARL's ROE is -0.62%, compared to AORT's ROE of +0.03%. Regarding short-term risk, CARL is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check AORT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while IART trades at $16.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas IART's P/E ratio is 7.06. In terms of profitability, CARL's ROE is -0.62%, compared to IART's ROE of -0.01%. Regarding short-term risk, CARL is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for CARL.Check IART's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AVNS's P/E ratio is 27.77. In terms of profitability, CARL's ROE is -0.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CARL is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for CARL.Check AVNS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while IRMD trades at $90.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas IRMD's P/E ratio is 45.66. In terms of profitability, CARL's ROE is -0.62%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, CARL is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for CARL.Check IRMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SILK's P/E ratio is -18.96. In terms of profitability, CARL's ROE is -0.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CARL is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SILK's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas FNA's P/E ratio is -19.83. In terms of profitability, CARL's ROE is -0.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CARL is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for CARL.Check FNA's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PRCT trades at $18.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PRCT's P/E ratio is -10.23. In terms of profitability, CARL's ROE is -0.62%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, CARL is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for CARL.Check PRCT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while LMRI trades at $10.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas LMRI's P/E ratio is -20.25. In terms of profitability, CARL's ROE is -0.62%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, CARL is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for CARL.Check LMRI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BVS has a market cap of 892.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BVS trades at $13.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BVS's P/E ratio is 17.56. In terms of profitability, CARL's ROE is -0.62%, compared to BVS's ROE of +0.16%. Regarding short-term risk, CARL is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BVS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, INMD has a market cap of 870.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while INMD trades at $15.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas INMD's P/E ratio is 9.71. In terms of profitability, CARL's ROE is -0.62%, compared to INMD's ROE of +0.13%. Regarding short-term risk, CARL is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check INMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CSII's P/E ratio is -20.83. In terms of profitability, CARL's ROE is -0.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CARL is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for CARL.Check CSII's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SIBN has a market cap of 787.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SIBN trades at $17.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SIBN's P/E ratio is -45.54. In terms of profitability, CARL's ROE is -0.62%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SIBN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SSII has a market cap of 784.5M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SSII trades at $3.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SSII's P/E ratio is -76.46. In terms of profitability, CARL's ROE is -0.62%, compared to SSII's ROE of -0.23%. Regarding short-term risk, CARL is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for CARL.Check SSII's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CBLL has a market cap of 671.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CBLL trades at $17.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CBLL's P/E ratio is -10.85. In terms of profitability, CARL's ROE is -0.62%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, CARL is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for CARL.Check CBLL's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, TCMD has a market cap of 635.4M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while TCMD trades at $28.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas TCMD's P/E ratio is 32.01. In terms of profitability, CARL's ROE is -0.62%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check TCMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CARL's ROE is -0.62%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SRDX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BWAY has a market cap of 597.4M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BWAY trades at $15.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BWAY's P/E ratio is 38.69. In terms of profitability, CARL's ROE is -0.62%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, CARL is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BWAY's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas APEN's P/E ratio is -9.43. In terms of profitability, CARL's ROE is -0.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CARL is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for CARL.Check APEN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BBNX has a market cap of 577.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BBNX trades at $12.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BBNX's P/E ratio is -8.50. In terms of profitability, CARL's ROE is -0.62%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, CARL is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BBNX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CTKB has a market cap of 545M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CTKB trades at $4.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CTKB's P/E ratio is -32.46. In terms of profitability, CARL's ROE is -0.62%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, CARL is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for CARL.Check CTKB's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CARL's ROE is -0.62%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, CARL is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ZIMV's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, KIDS has a market cap of 518.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while KIDS trades at $20.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas KIDS's P/E ratio is -19.60. In terms of profitability, CARL's ROE is -0.62%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, CARL is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for CARL.Check KIDS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, OFIX has a market cap of 477M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while OFIX trades at $11.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas OFIX's P/E ratio is -48.07. In terms of profitability, CARL's ROE is -0.62%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, CARL is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for CARL.Check OFIX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, VREX has a market cap of 471.1M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while VREX trades at $11.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas VREX's P/E ratio is 11.78. In terms of profitability, CARL's ROE is -0.62%, compared to VREX's ROE of -0.18%. Regarding short-term risk, CARL is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for CARL.Check VREX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CLPT has a market cap of 448M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CLPT trades at $14.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CLPT's P/E ratio is -14.79. In terms of profitability, CARL's ROE is -0.62%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, CARL is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for CARL.Check CLPT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, NPCE has a market cap of 439.5M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while NPCE trades at $12.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas NPCE's P/E ratio is -22.22. In terms of profitability, CARL's ROE is -0.62%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, CARL is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for CARL.Check NPCE's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PACB has a market cap of 434.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PACB trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PACB's P/E ratio is -2.86. In terms of profitability, CARL's ROE is -0.62%, compared to PACB's ROE of -4.88%. Regarding short-term risk, CARL is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for CARL.Check PACB's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CERS has a market cap of 430.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CERS trades at $2.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CERS's P/E ratio is -42.91. In terms of profitability, CARL's ROE is -0.62%, compared to CERS's ROE of -0.10%. Regarding short-term risk, CARL is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for CARL.Check CERS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, DCTH has a market cap of 421.9M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while DCTH trades at $12.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas DCTH's P/E ratio is 1222.00. In terms of profitability, CARL's ROE is -0.62%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, CARL is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for CARL.Check DCTH's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ELMD has a market cap of 336.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ELMD trades at $40.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ELMD's P/E ratio is 34.72. In terms of profitability, CARL's ROE is -0.62%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, CARL is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ELMD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CV has a market cap of 328.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CV trades at $6.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CV's P/E ratio is -2.63. In terms of profitability, CARL's ROE is -0.62%, compared to CV's ROE of +1.27%. Regarding short-term risk, CARL is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for CARL.Check CV's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CARL's ROE is -0.62%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, CARL is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SMLR's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, AVR has a market cap of 288.4M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while AVR trades at $7.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas AVR's P/E ratio is -3.52. In terms of profitability, CARL's ROE is -0.62%, compared to AVR's ROE of -1.24%. Regarding short-term risk, CARL is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for CARL.Check AVR's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SGHT has a market cap of 286.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SGHT trades at $5.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SGHT's P/E ratio is -7.41. In terms of profitability, CARL's ROE is -0.62%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, CARL is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check SGHT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, TMCI has a market cap of 279.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while TMCI trades at $4.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas TMCI's P/E ratio is -4.59. In terms of profitability, CARL's ROE is -0.62%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, CARL is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for CARL.Check TMCI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PROF has a market cap of 268.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PROF trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PROF's P/E ratio is -5.95. In terms of profitability, CARL's ROE is -0.62%, compared to PROF's ROE of -0.70%. Regarding short-term risk, CARL is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for CARL.Check PROF's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ANIK has a market cap of 256.5M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ANIK trades at $19.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ANIK's P/E ratio is 39.35. In terms of profitability, CARL's ROE is -0.62%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, CARL is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for CARL.Check ANIK's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, RXST has a market cap of 248.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while RXST trades at $6.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas RXST's P/E ratio is -8.35. In terms of profitability, CARL's ROE is -0.62%, compared to RXST's ROE of -0.17%. Regarding short-term risk, CARL is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for CARL.Check RXST's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas MGRM's P/E ratio is -12.00. In terms of profitability, CARL's ROE is -0.62%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, CARL is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for CARL.Check MGRM's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, FOCL has a market cap of 229.4M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while FOCL trades at $6.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas FOCL's P/E ratio is -7.87. In terms of profitability, CARL's ROE is -0.62%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, CARL is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for CARL.Check FOCL's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CARL's ROE is -0.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CARL is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for CARL.Check NVRO's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CATX has a market cap of 223.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CATX trades at $2.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CATX's P/E ratio is -2.05. In terms of profitability, CARL's ROE is -0.62%, compared to CATX's ROE of -0.42%. Regarding short-term risk, CARL is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for CARL.Check CATX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, SENS has a market cap of 210.2M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while SENS trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas SENS's P/E ratio is -2.51. In terms of profitability, CARL's ROE is -0.62%, compared to SENS's ROE of -1.30%. Regarding short-term risk, CARL is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for CARL.Check SENS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CARL's ROE is -0.62%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, CARL is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for CARL.Check BSGM's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CARL's ROE is -0.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CARL is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for CARL.Check MDGS's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, INGN has a market cap of 174.6M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while INGN trades at $6.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas INGN's P/E ratio is -7.09. In terms of profitability, CARL's ROE is -0.62%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CARL is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for CARL.Check INGN's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, TLSI has a market cap of 172.1M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while TLSI trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas TLSI's P/E ratio is -2.70. In terms of profitability, CARL's ROE is -0.62%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, CARL is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for CARL.Check TLSI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, QTRX has a market cap of 163.9M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while QTRX trades at $3.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas QTRX's P/E ratio is -2.17. In terms of profitability, CARL's ROE is -0.62%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, CARL is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for CARL.Check QTRX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CARL's ROE is -0.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check QIPT's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, STIM has a market cap of 137.8M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while STIM trades at $1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas STIM's P/E ratio is -3.67. In terms of profitability, CARL's ROE is -0.62%, compared to STIM's ROE of -1.65%. Regarding short-term risk, CARL is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for CARL.Check STIM's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, CVRX has a market cap of 137.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while CVRX trades at $5.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas CVRX's P/E ratio is -2.56. In terms of profitability, CARL's ROE is -0.62%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, CARL is less volatile compared to CVRX. This indicates lower risk in terms of short-term price fluctuations for CARL.Check CVRX's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, PMI has a market cap of 137.1M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while PMI trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas PMI's P/E ratio is -0.07. In terms of profitability, CARL's ROE is -0.62%, compared to PMI's ROE of +4.99%. Regarding short-term risk, CARL is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for CARL.Check PMI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, RCEL has a market cap of 109.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while RCEL trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas RCEL's P/E ratio is -2.80. In terms of profitability, CARL's ROE is -0.62%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, CARL is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for CARL.Check RCEL's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas ICAD's P/E ratio is -20.37. In terms of profitability, CARL's ROE is -0.62%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, CARL is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for CARL.Check ICAD's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas HJLI's P/E ratio is N/A. In terms of profitability, CARL's ROE is -0.62%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, CARL is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for CARL.Check HJLI's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, RPID has a market cap of 96.5M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while RPID trades at $2.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas RPID's P/E ratio is -1.90. In terms of profitability, CARL's ROE is -0.62%, compared to RPID's ROE of -1.32%. Regarding short-term risk, CARL is more volatile compared to RPID. This indicates higher risk in terms of short-term price fluctuations for CARL.Check RPID's competition here

Carlsmed, Inc. (NASDAQ: CARL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CARL stands at 342.3M. In comparison, HSDT has a market cap of 96.3M. Regarding current trading prices, CARL is priced at $12.59 on the NASDAQ, while HSDT trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CARL currently has a P/E ratio of -5.02, whereas HSDT's P/E ratio is -0.02. In terms of profitability, CARL's ROE is -0.62%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, CARL is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for CARL.Check HSDT's competition here